Bitwise has filed for an ETF focused on AI drug discovery, extending the industry’s push into highly specialized thematic funds. ETF analyst James Seyffart back

Bitwise has filed for an ETF focused on AI drug discovery, extending the industry’s push into highly specialized thematic funds. ETF analyst James Seyffart backed the move, casting it as a bet on a potentially important biotech-AI growth area.